Treatment Related Cancer
Conditions
Keywords
colorectal cancer, FIRE, low-RAS, mCRC, Panitumumab
Brief summary
The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS mutation when the majority of tumor cells is still sensitive. While response rate may be high and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS wild-type patients due to the faster development of resistance when sensitive cells are eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant. The characteristics of low-level RAS mutant tumors would be: * Objective response rate (ORR) high (reflecting the sensitive clone) * Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant clones)
Interventions
DRUGPanitumumab
Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1 \*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
DRUGIrinotecan
Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
DRUGFolinic acid
Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
DRUG5-FU
5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
Sponsors
Ludwig-Maximilians - University of Munich
Amgen
ClinAssess GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed, UICC stage IV metastatic adenocarcinoma of the colon or rectum * Primarily non-resectable metastases or surgical resection refused by the patient * RAS mutation determined by the local pathology * Age ≥18 * ECOG performance status 0-2 * Patients suitable for chemotherapy administration * Patient's written declaration of consent obtained * Estimated life expectancy \> 3 months * Presence of at least one measurable reference lesion according to the RECIST 1.1 criteria * Primary tumor tissue available and patient consents to storage and molecular and genetic profiling of tumor material. Molecular profiling of blood samples is optionally performed. * Adequate bone marrow function: * Leukocytes ≥ 3.0 x 109/L with neutrophils ≥ 1.5 x 109/L * Thrombocytes ≥ 100 x 109/L * Haemoglobin ≥ 5.6 mmol/L (equivalent to 9 g/dL) * Adequate hepatic function: * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) * ALAT and ASAT ≤ 2.5 x ULN (in the presence of hepatic metastases, ALAT and ASAT ≤ 5 x ULN) * Adequate renal function: ▫ Creatinine clearance (calculated according to Cockcroft and Gault) ≥ 50 mL/min * No previous chemotherapy for metastatic disease. Patient with need of immediate treatment (high tumor load, symptoms) may have received one application of FOLFIRI prior to study treatment.
Exclusion criteria
* Previous chemotherapy for metastatic disease with the exception of one cycle of FOLFIRI (e.g. while waiting for the result of RAS mutation frequency). * Patients planned to be treated with FOLFOX or another oxaliplatin-based regimen as first-line treatment * Primarily resectable metastases and the patient agrees to resection * Grade III or IV heart failure (NYHA classification) * Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study * Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study * Participation in an investigational clinical study or experimental drug treatment within 30 days prior to study inclusion or within a period of 5 half-lives of the substances administered in the investigational clinical study or during an experimental drug treatment prior to inclusion in the study, depending on which period is longest * Known hypersensitivity or allergic reaction to any of the following substances: 5-fluorouracil, folinic acid, panitumumab, irinotecan, and chemically related substances and/or hypersensitivity to any of the excipients of any of the aforementioned substances including known hypersensitivity reactions to monoclonal antibodies NCI CTCAE Grade ≥ 3. * Known hypersensitivity to Chinese hamster ovary cell (CHO) - cellular products or other recombinant human or humanised monoclonal antibodies * History of uncontrolled bronchial asthma * Patients with interstitial pneumonitis or pulmonary fibrosis * Patients with known brain metastasis * History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea * Symptomatic peritoneal carcinomatosis * Severe, non-healing wounds, ulcers or bone fractures * Patients with acute or chronic infection requiring systemic therapy * Known history of positive testing for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) * Active or chronic Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive; serologic tests required in patients who receive study treatment). * Known DPD deficiency (specific screening not required) * Known glucuronidation deficiency (Gilbert's syndrome);(specific screening not required * Treatment with sorivudine or brivudine within 28 days before study enrollment or requirement for concomitant antiviral treatment with sorivudine or brivudine * History of a second primary malignancy during the past 5 years before inclusion in the study or during participation in the study, with the exception of a basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, if these were treated curatively. * Known previous or ongoing alcohol or drug abuse * Pregnant or breast-feeding patients * Any other severe concomitant disease or disorder which, in the investigator's opinion, could influence the patient's ability to participate in the study or influence his/her safety during the study or interfere with interpretation of study results * Both, absent and restricted legal capacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | up to 60 months | As primary endpoint ORR according to RECIST 1.1 will be evaluated separately for each arm of patients with defined low-frequency RAS mutation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | up to 60 months | PFS, separately for each arm of patients with defined low-frequency RAS mutation |
| Overall Survival (OS) | up to 60 months | OS, separately for each arm of patients with defined low-frequency RAS mutation |
| Investigation of Early Tumor shrinkage (ETS) as an alternative early-on-treatment predictor of treatment efficacy | up to 48 months | ETS, separately for each group of patients with defined low-frequency RAS mutation |
| Investigation of Depth of Response (DpR) to define the nadir of tumour response | up to 48 months | DpR, separately for each arm of patients with defined low-frequency RAS Mutation. |
Countries
Germany
Contacts
STUDY_CHAIRDominik Modest, PD Dr.
Ludwigs Maximilians University Munich
Outcome results
None listed